ÂÜÀòÂÒÂ×

Daša Lipovšek is Vice President and Head of Lead Discovery at Aktis Oncology, where she is responsible for the discovery of target-binding mini-protein leads suitable for development into radiopharmaceuticals. Prior to joining Aktis, Daša spent 12 years at Bristol Myers Squibb, most recently as Scientific Associate Director, Selection Technologies and Protein Engineering. Her earlier roles include Director, Protein Design, at Adnexus Therapeutics, a Bristol Myers Squibb R&D Company; Director of Protein Engineering at Codon Devices; Visiting Scientist in Biological Engineering at MIT; and Associate Director of Biochemistry at Phylos. Throughout her last 25 years in the biopharma industry, Daša has combined structure-based design and in vitro evolution to identify target-binding proteins for use as therapeutic and diagnostic agents, with a particular emphasis on designed single-domain proteins.

Daša received a SB in Biology from MIT and a PhD in Chemistry from the University of Cambridge. Her hobbies are clicker training of horses, dogs, and cats, and open-water swimming.